StockNews.AISignal intelligence
Company intelligence

KRYS

Krystal Biotech, Inc. · NASDAQ · Healthcare

Price$315.82+0.15% · +$0.48
Market cap9.36BEquity value
P / E39.6Trailing ratio
Volume295.87KLatest session
Market data

KRYS price chart

TradingView
Related signals
1 min delayed

Browse public KRYS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

KRYSNov 2, 2026-8.77% since signal

Krystal Biotech reports strong 3Q revenue, completes pricing talks, and launches $400M buyback

Krystal Biotech posted a solid 3Q with $127.3 million in VYJUVEK revenue and $1.1 billion since launch, plus completed pricing negotiations in Germany and Italy. KB113 clinical data show regression in more than 80% of Gorlin syndrome basal cell carcinoma lesions, supporting therapeutic potential. The company closed the quarter with $1.2 billion in cash and investments and authorized a $400 million share repurchase, signaling robust capital flexibility and upside potential.

View signal analysis
KRYSSep 15, 2025+0.53% since signal

FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

FDA approved KRYS label update for Vyjuvek, expanding patient eligibility. New update enhances flexibility in managing wound dressings for patients. Real-world data supports Vyjuvek's long-term safety and efficacy. Analysts believe current valuation underestimates Vyjuvek's revenue potential. KRYS stock increased 6.01% following the label update announcement.

View signal analysis
KRYSMay 23, 2024-2.22% since signal

Earnings Estimates Moving Higher for Krystal Biotech (KRYS): Time to Buy?

- KRYS is an attractive pick with improving earnings outlook and strong stock performance. - Analysts' optimism on earnings drives estimates higher, potentially impacting stock price. - Zacks Rank system shows strong correlation between earnings estimate revisions and stock price movements. - Current-quarter EPS estimate: $0.46 per share, +136.8% YoY. Current-year EPS estimate: $2.06 per share, +174.64% YoY. - KRYS has a Zacks Rank #2 (Buy) due to promising estimate revisions, outperforming S&P 500. Price Impact Rating: Bullish Impact Horizon Rating: Short-term Type: Research Analysis

View signal analysis
KRYSMay 3, 2024

Why Krystal Biotech (KRYS) Might Surprise This Earnings Season

- Krystal Biotech (KRYS) has favorable earnings estimate revisions, potentially leading to an earnings beat. - The Most Accurate Estimate for the current quarter is higher than the Zacks Consensus Estimate. - Positive Zacks Earnings ESP and Zacks Rank #3 indicate potential positive surprise for investors. - Recent backtest shows stocks with similar indicators have returned over 28% annually. Price Impact Rating: bullish Impact Horizon Rating: short-term Type: Research Analysis

View signal analysis
Research

Company intelligence